Multicenter prospective follow-up of a not controlled chronic hepatitis C genotypes 2/3
patients cohort with treatment indication with interferon α 2b and ribavirin for 24 weeks,
and the verification of sustained virological response at week 48.
The eligibility criteria and outcome measures followed the Clinical Protocol and Therapeutic
Guidelines for Chronic Viral Hepatitis C, published by the Ministry of Health:
http://portal.saude.gov.br/portal/arquivos/pdf/pcdt_hepatite_c_2011_retificado.pdf
Phase:
Phase 4
Details
Lead Sponsor:
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Collaborators:
Hospital Federal de Bonsucesso (Bonsucesso Federal Hospital) Hospital Universitário Clementino Fraga Filho Hospital Universitário Clementino Fraga Filho (Clementino Fraga Filho University Hospital)